JUST THE FACTS: Omega-3s and Bleeding

Concerns about omega-3s and bleeding are not supported in scientific literature. 1-6

Research has found that supplementation of EPA and DHA up to 5g does not increase bleeding risk.^{1, 6, 7}

People with more omega-3s in their blood before surgery were not at higher risk of bleeding during and after surgery.⁵

Less than 0.001% of adverse event reports from the U.S. FDA noted abnormal or prolonged bleeding associated with fish oil.⁷

Research also supports that omega-3s are cardioprotective. EPA and DHA omega-3s help:

- Reduce the risk of cardiac death^{8,9}
- Reduce triglycerides¹⁰

- Reduce blood pressure¹¹
- Reduce the risk for myocardial infarction⁹

Allow blood to move freely by inhibiting clot formation without increasing the risk of bleeding⁴

The benefits of getting enough omega-3s far outweigh the clinically and statistically insignificant risks of bleeding.

Aim for at least 500 mg EPA + DHA omega-3s per day by eating fatty fish and/or taking a supplement.



References

- 1. Harris WS (2016). Fish Oils and Bleeding-Where Is the Evidence? JAMA Intern Med. 176:1405-6. doi: 10.1001/jamainternmed.2016.3968
- Harris WS (2007). Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 99:44C-46C. doi: 10.1016/j.amj-
- 3. Jeansen S, et al. (2018). Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: Analysis of 8 clinical studies with selected patient groups on omega-3-enriched medical nutrition. Clin Nutr. 37:948-57. doi: 10.1016/j.cl-
- 4. Begtrup KM, et al. (2017). No impact of fish oil supplements on bleeding risk: a systematic review. Dan Med J. 64:A5366. https://ug-eskriftet.dk/dmj/no-impact-fish-oil-supplements-bleeding-risk-systematic-review

 Akintoye E, et al. (2018). Fish Oil and Perioperative Bleeding. Circ Cardiovasc Qual Outcomes. 11:e004584. doi: 10.1161/CIRCOUT-COMES.118.004584
- 6. Javaid M, et al. (2024). Bleeding risk in patients receiving omega-3 polyunsaturated fatty acids: a systematic review and meta-analy-
- sis of randomized clinical trials. J Am Heart Assn. 13: e032390. doi:10.1161/JAHA.123.032390
 7. CFSAN Adverse Event Reporting System (CAERS). Online at https://www.fda.gov/food/compliance-enforcement-food/cfsan-adverse-event-reporting-system-caers
- 8. Maki KC et al. (2017). Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. J Clin Lipidol. 11:1152-60. doi:10.1016/j.jacl.2017.07.010 9. Bernasconi AA, et al. (2021). Omega-3 benefits remain strong post-STRENGTH. Mayo Clin Proc. 96:1371-72. Doi: https://doi.org/10.1016/j.-
- 9. Berhasconi AA, et al. (20ci). Onlega-3 benefits remain storing post-3 retrianded and analysis of anyocp.2020.08.034

 10. Balk EM, et al. (2006). Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 189:19-30. doi:10.1016/j.atherosclerosis.2006.02.012

 11. Miller PE, et al. (2014). Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 27:885–96. doi:10.1093/ajh/hpu024

This content is for healthcare professionals only.

